Biopharmaceutical Company Seeking Talent, Plans to Hire Up to 40 Employees
Vero Biotech is pleased to announce the opening of its new corporate headquarters in Georgia Tech’s Technology Enterprise Park on April 6, 2018. Vero Biotech, formerly GeNO LLC, is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled Nitric Oxide (NO) delivery systems to address unmet needs of patients with cardiopulmonary conditions.
“We are excited to be moving to Atlanta, where we will have access to a growing biotech community housed at Technology Enterprise Park, part of the Georgia Techcommunity; a highly skilled workforce; and an innovation support system that is essential for a startup company like Vero Biotech,”says Brent Furse, President and CEO of Vero Biotech. “It is significant for us to be able to work in an advanced new complex. The modern facility will enable us to continue to accommodate the growing needs of our research, development, and commercial opportunities.”
Vero Biotech will be moving their Administrative, Research & Development, and Manufacturing capabilities from Cocoa, Florida, to Atlanta during the next six to 12 months. Currently, Vero Biotech has approximately 65 employees and plans to hire up to 40 more over the next year.
“We expect to double in size during the next 12 to 18 months, and we will be looking to hire top talent, especially in the areas of software development, engineering, sales and marketing, and quality assurance,” said Marc Morin, CFO of Vero Biotech. “We encourage anyone interested in these outstanding opportunities to visit our website: www.vero-biotech.com.”
In their new location, Vero Biotech will partner with Georgia Tech to provide hands-on experience and internship opportunities for the future leaders of the biotech industry.
“We are pleased to welcome innovative biotech companies like Vero Biotech to Atlanta,” said Russell Allen, President and CEO of Georgia Bio. “Adding to our region’s unique mix of people, facilities, and resources helps position Atlanta as one of the leading global bioscience hubs.”
Chad Koenig and Ben Jackson of Cushman & Wakefield represented Vero Biotech in the 15,585-square-foot lease, and Enio Guerra and Dick Bowers of Richard Bowers & Co. represented the landlord.
For more information, contact Vero Biotech on Facebook, LinkedIn, or on their website.
About Vero Biotech
Vero Biotech (formerly known as GeNO LLC), is a biopharmaceutical company focused on the design development and commercialization of next generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
